Skip to Content

Clinical Trial Details

Standard Chemotherapy Versus High Dose Chemotherapy With Stem Cell Transplant For Myeloma Patients

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age.

Objective

To determine if high dose chemotherapy followed by stem cell transplant is still necessary in the initial management of multiple myeloma in younger patients.

Inclusion Criteria:
Must have one or more organs damaged by myeloma. Must have disease that is measureable in blood or urine test.

IRB Protocol Number
DFCI 10-106

Clinical Trial Categories

  • Lymphoma/Lymph Node/Leukemia/Blood-related Cancers
Contact
Margaret White, RN OCN, CC at 603-232-8908

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000